The vast majority of modern pharmaceuticals for the treatment of AD rely on AChE inhibition, however, newer approaches are oriented towards dual targeting of both enzymes, partly to more effectively restore the AchE balance, but also on the account that both enzymes take part in Aβ aggregation [4,8]. This evidence concerns the gene ACHE and Alzheimer disease.